7775.T
Daiken Medical Co., Ltd. [7775.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
7775.T Stock Summary
Top 10 Correlated ETFs
7775.T
Top 10 Correlated Stocks
7775.T
In the News
7775.T Financial details
Company Rating
Strong Buy
Market Cap
15.71B
Income
754.5M
Revenue
9.3B
Book val./share
227.24
Cash/share
86.63
Dividend
20
Dividend %
3.77%
Employees
188
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
20.22
Forward P/E
-
PEG
-21.99
P/S
1.64
P/B
2.34
P/C
6.13
P/FCF
-
Quick Ratio
1.05
Current Ratio
1.87
Debt / Equity
0.42
LT Debt / Equity
0.14
-
-
EPS (TTM)
26.27
EPS next Y
-
EPS next Q
-
EPS this Y
-14.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.12%
Revenue last 5Y
1.68%
Revenue Q/Q
5.4%
EPS Q/Q
914.29%
-
-
-
-
SMA20
0.56%
SMA50
6.79%
SMA100
10.18%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
11%
ROC
0.15%
Gross Margin
38%
Oper. Margin
12%
Profit Margin
8%
Payout
-
Shs Outstand
28.73M
Shs Float
13.41M
-
-
-
-
Target Price
-
52W Range
440.0-565.0
52W High
-6.02%
52W Low
+20.68%
RSI
38.48
Rel Volume
0.56
Avg Volume
47.1K
Volume
26.3K
Perf Week
-2.57%
Perf Month
-1.12%
Perf Quarter
12.03%
Perf Half Y
7.93%
-
-
-
-
Beta
0.144587
-
-
Volatility
5.75%, 9.1%
Prev Close
-1.12%
Price
531
Change
-0.56%
7775.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 286.78 | 296.69 | 273.67 | 297.28 | 318.05 | |
| Net income per share | 29.05 | 29.92 | 23.5 | 28.93 | 24.79 | |
| Operating cash flow per share | 30.05 | 50.02 | 21.2 | 39.46 | 34.43 | |
| Free cash flow per share | 22.98 | 44.13 | 10.34 | 32.39 | 27.5 | |
| Cash per share | 71.71 | 79.86 | 73.14 | 87.67 | 85.24 | |
| Book value per share | 196.77 | 211.69 | 215.2 | 224.38 | 229.64 | |
| Tangible book value per share | 195.67 | 210.67 | 214.44 | 223.85 | 229.31 | |
| Share holders equity per share | 196.77 | 211.69 | 215.2 | 224.38 | 229.64 | |
| Interest debt per share | 117.86 | 101.77 | 103.01 | 101.81 | 94.81 | |
| Market cap | 16.33B | 18.87B | 17.5B | 14.65B | 13.82B | |
| Enterprise value | 17.56B | 19.43B | 18.28B | 15.05B | 14.02B | |
| P/E ratio | 19.17 | 21.96 | 25.91 | 17.63 | 19.41 | |
| Price to sales ratio | 1.94 | 2.21 | 2.23 | 1.72 | 1.51 | |
| POCF ratio | 18.53 | 13.14 | 28.72 | 12.92 | 13.97 | |
| PFCF ratio | 24.23 | 14.89 | 58.88 | 15.75 | 17.49 | |
| P/B Ratio | 2.83 | 3.1 | 2.83 | 2.27 | 2.09 | |
| PTB ratio | 2.83 | 3.1 | 2.83 | 2.27 | 2.09 | |
| EV to sales | 2.09 | 2.28 | 2.33 | 1.76 | 1.53 | |
| Enterprise value over EBITDA | 11.3 | 13.24 | 15.01 | 10.24 | 10.58 | |
| EV to operating cash flow | 19.93 | 13.52 | 30.01 | 13.28 | 14.18 | |
| EV to free cash flow | 26.06 | 15.33 | 61.52 | 16.18 | 17.75 | |
| Earnings yield | 0.05 | 0.05 | 0.04 | 0.06 | 0.05 | |
| Free cash flow yield | 0.04 | 0.07 | 0.02 | 0.06 | 0.06 | |
| Debt to equity | 0.6 | 0.48 | 0.48 | 0.45 | 0.41 | |
| Debt to assets | 0.31 | 0.27 | 0.27 | 0.27 | 0.25 | |
| Net debt to EBITDA | 0.79 | 0.38 | 0.64 | 0.27 | 0.15 | |
| Current ratio | 1.71 | 1.69 | 1.87 | 2.09 | 1.97 | |
| Interest coverage | 262.3 | 262.45 | 241.98 | 307.97 | 265.94 | |
| Income quality | 0.76 | 1.21 | 0.64 | 0.98 | 0.97 | |
| Dividend Yield | 0.05 | 0.03 | 0.03 | 0.04 | 0.04 | |
| Payout ratio | 0.91 | 0.64 | 0.85 | 0.69 | 0.79 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.24 | -0.12 | -0.51 | -0.18 | -0.2 | |
| Capex to revenue | -0.02 | -0.02 | -0.04 | -0.02 | -0.02 | |
| Capex to depreciation | -0.68 | -0.67 | -1.22 | -0.65 | -0.74 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 358.63 | 377.51 | 337.35 | 382.16 | 357.86 | |
| ROIC | 0.1 | 0.1 | 0.07 | 0.09 | 0.08 | |
| Return on tangible assets | 0.08 | 0.08 | 0.06 | 0.08 | 0.06 | |
| Graham Net | -13.33 | -20.64 | -18.9 | -5.55 | -7.66 | |
| Working capital | 2.64B | 2.62B | 2.93B | 3.42B | 3.27B | |
| Tangible asset value | 5.74B | 6.05B | 6.16B | 6.43B | 6.59B | |
| Net current asset value | 1.14B | 1.49B | 1.7B | 2.1B | 2.22B | |
| Invested capital | 0.6 | 0.48 | 0.48 | 0.45 | 0.41 | |
| Average receivables | 2.78B | 2.27B | 1.77B | 1.49B | 1.34B | |
| Average payables | 883.16M | 901.64M | 891.41M | 636.77M | 493.19M | |
| Average inventory | 1.37B | 1.34B | 1.3B | 1.48B | 1.53B | |
| Days sales outstanding | 113.48 | 82.34 | 75.25 | 58.38 | 52.72 | |
| Days payables outstanding | 68.35 | 73.65 | 66.17 | 34.36 | 34.45 | |
| Days of inventory on hand | 122.51 | 89.42 | 115.26 | 116.08 | 98.6 | |
| Receivables turnover | 3.22 | 4.43 | 4.85 | 6.25 | 6.92 | |
| Payables turnover | 5.34 | 4.96 | 5.52 | 10.62 | 10.6 | |
| Inventory turnover | 2.98 | 4.08 | 3.17 | 3.14 | 3.7 | |
| ROE | 0.15 | 0.14 | 0.11 | 0.13 | 0.11 | |
| Capex per share | -7.07 | -5.89 | -10.86 | -7.07 | -6.93 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q1
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 76.46 | 78.61 | 84.99 | 78 | 82.21 | |
| Net income per share | 7.04 | 7.9 | 9.01 | 0.83 | 8.52 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 81.16 | 79.45 | 72.15 | 85.24 | 86.63 | |
| Book value per share | 220.55 | 228.57 | 228.69 | 229.64 | 227.24 | |
| Tangible book value per share | 220.55 | 228.57 | 228.69 | 229.31 | 227.24 | |
| Share holders equity per share | 220.55 | 228.57 | 228.69 | 229.64 | 227.24 | |
| Interest debt per share | 100.31 | 94.35 | 89.96 | 94.71 | 96.06 | |
| Market cap | 13.99B | 13.39B | 12.9B | 13.82B | 15.05B | |
| Enterprise value | 14.54B | 13.81B | 13.41B | 14.02B | 15.32B | |
| P/E ratio | 17.29 | 14.75 | 12.46 | 144.33 | 15.38 | |
| Price to sales ratio | 6.37 | 5.93 | 5.28 | 6.17 | 6.37 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 2.21 | 2.04 | 1.96 | 2.09 | 2.31 | |
| PTB ratio | 2.21 | 2.04 | 1.96 | 2.09 | 2.31 | |
| EV to sales | 6.62 | 6.12 | 5.49 | 6.26 | 6.49 | |
| Enterprise value over EBITDA | 50.29 | 43.46 | 36.76 | 163.48 | 44.66 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0.01 | 0.02 | 0.02 | 0 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.45 | 0.41 | 0.39 | 0.41 | 0.42 | |
| Debt to assets | 0.27 | 0.25 | 0.24 | 0.25 | 0.25 | |
| Net debt to EBITDA | 1.9 | 1.34 | 1.4 | 2.37 | 0.79 | |
| Current ratio | 2.02 | 2.08 | 1.88 | 1.97 | 1.87 | |
| Interest coverage | 294.49 | 319.24 | 384.33 | 81.06 | 281.47 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 186.94 | 201.56 | 215.32 | 65.61 | 208.72 | |
| ROIC | 0.02 | 0.02 | 0.03 | 0 | 0.03 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0 | 0.02 | |
| Graham Net | -10.77 | -7.33 | -10.85 | -7.66 | -9.63 | |
| Working capital | 3.26B | 3.38B | 3.09B | 3.27B | 3.09B | |
| Tangible asset value | 6.32B | 6.55B | 6.56B | 6.59B | 6.52B | |
| Net current asset value | 2.03B | 2.26B | 2.26B | 2.22B | 2.17B | |
| Invested capital | 0.45 | 0.41 | 0.39 | 0.41 | 0.42 | |
| Average receivables | 1.35B | 1.3B | 1.37B | 1.39B | 1.29B | |
| Average payables | 454.05M | 457.45M | 495.88M | 528.49M | 529.69M | |
| Average inventory | 1.56B | 1.61B | 1.66B | 1.59B | 1.54B | |
| Days sales outstanding | 54.47 | 50.65 | 53.99 | 53.01 | 47.98 | |
| Days payables outstanding | 31.65 | 31.37 | 32.93 | 30.7 | 33.99 | |
| Days of inventory on hand | 110.07 | 111.88 | 104.39 | 87.88 | 100.5 | |
| Receivables turnover | 1.65 | 1.78 | 1.67 | 1.7 | 1.88 | |
| Payables turnover | 2.84 | 2.87 | 2.73 | 2.93 | 2.65 | |
| Inventory turnover | 0.82 | 0.8 | 0.86 | 1.02 | 0.9 | |
| ROE | 0.03 | 0.03 | 0.04 | 0 | 0.04 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
7775.T Frequently Asked Questions
What is Daiken Medical Co., Ltd. stock symbol ?
Daiken Medical Co., Ltd. is a JP stock and trading under the symbol 7775.T
What is Daiken Medical Co., Ltd. stock quote today ?
Daiken Medical Co., Ltd. stock price is $531 today.
Is Daiken Medical Co., Ltd. stock public?
Yes, Daiken Medical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 47.1K
- Market Capitalization 15.71B
- Employee 188
- CEO Mr. Keiichi Yamada
- Headquarters Izumi,JP
- IPO Date 2009-03-12
-
Website
https://www.daiken-iki.co.jp 
Daiken Medical Co., Ltd. manufactures and distributes medical devices and equipment in Japan and internationally. The company offers syringe pumps, disposable infusion pumps, portable disposable infusers, endobronchial blocker tubes, suction containers, connecting tubes, suction tips, medical hand washing machines, disposable medical towels, sterilize mats, and wet disinfectant mats. It also trades in medical equipment. The company sells its products under the COOPDECH brand. Daiken Medical Co., Ltd. was incorporated in 1968 and is headquartered in Izumi, Japan.
